INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
INmune Bio said the UK MHRA accepted written minutes from a May 12 pre-MAA Scientific Advice meeting for CORDStrom™/Ebstrocel™ in recessive dystrophic epidermolysis bullosa (RDEB). The agency aligned on CMC, non-clinical and clinical evidence, and noted MissionEB Phase 2 showed clinically meaningful symptomatic benefit (pain, itch), supporting chronic/intermittent supportive therapy positioning. The company plans a 2026 UK conditional MAA, with EU and US filings later.
How this was made
The 30-second read
Why it matters
Accepted MHRA written alignment across CMC, non-clinical safety, and clinical evidence strategy reduces regulatory uncertainty for the planned 2026 UK conditional marketing authorization application. MHRA also provided pediatric investigation plan feedback, recognizing symptomatic benefits (pain/pruritus) while noting limitations on durable wound closure—driving endpoint refinements and confirmatory Phase 3 design changes.
Market read
This is a concrete regulatory milestone (accepted MHRA minutes) that clarifies what the company must deliver for a 2026 UK conditional MAA, including manufacturing transition and clinical/statistical evidence expectations.
What to watch
The minutes emphasize limitations in durable wound closure and the need to refine endpoints/statistics; investors may focus on whether Phase 3 can demonstrate durable, patient-relevant outcomes and manage manufacturing transition risk.
Background
INmune Bio’s Ebstrocel (Ebstrocel™/Ebstrocel in RDEB) is an RDEB-specific formulation derived from its CORDStrom pooled, off-the-shelf hucMSC platform; the company sought MHRA pre-MAA Scientific Advice to align on the UK conditional MAA package.
Ticker impact
INmune Bio received accepted MHRA pre-MAA Scientific Advice minutes supporting a planned 2026 UK Conditional Marketing Authorization filing for Ebstrocel in RDEB.
Likely near-term positive bias as the market prices reduced regulatory uncertainty ahead of the 2026 submission; magnitude depends on current valuation and burn-rate expectations.
The article is a primary regulatory milestone (accepted minutes) with specific guidance on CMC/manufacturing transition, non-clinical safety package, and clinical evidence/statistical approach for the MAA/PIP.
Market effects
Supports the broader cell-therapy/regenerative-medicine regulatory pathway for conditional approvals in ultra-rare diseases, including acceptance of Bayesian/qualitative evidence.
UK MHRA alignment may improve investor confidence in UK regulatory timelines for orphan cell therapies.
Could inform later EMA/FDA interactions, potentially affecting read-across sentiment for similar allogeneic MSC programs.
Counterpoint
Conditional authorization still depends on confirmatory Phase 3 execution; MHRA alignment may not translate into approval if endpoints (especially durability/wound closure) remain challenging.
Key entities
- companyINmune Bio Inc.
NASDAQ-listed late-stage biotech receiving accepted MHRA pre-MAA minutes for Ebstrocel in RDEB.
- regulatorMHRA
UK Medicines & Healthcare products Regulatory Agency providing written alignment on the pre-MAA package.
- product_candidateEbstrocel™ (Ebstrocel)
RDEB-specific investigational formulation derived from CORDStrom pooled hucMSC platform.
- platformCORDStrom™
Pooled, allogeneic, off-the-shelf hucMSC platform used to derive indication-specific formulations.
- diseaseRDEB
Recessive Dystrophic Epidermolysis Bullosa; ultra-rare disease with small patient populations.
